Phase 2b Study to Assess Efficacy and Safety of Bulevirtide With Peginterferon Alfa-2a in Patients With CHD

Condition:   Hepatitis D, Chronic Interventions:   Drug: Bulevirtide;   Drug: Peginterferon Alfa-2a Sponsors:   MYR GmbH;   Hepatera Ltd. Not yet recruiting

Source: ClinicalTrials.gov - February 25, 2019 Category: Research Source Type: clinical trials